Cerebral Toxoplasmosis
Conditions
Keywords
Cerebral toxoplasmosis, HIV, Immunodeficiencies, Hematopoietic stem, stem cell transplantation
Brief summary
Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Adult (≥18 years) * Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary). * At least one positive toxoplasmosis PCR test (regardless of tissue)
Exclusion criteria
* Subject who has expressed opposition to the reuse of their data for scientific research. * HIV positive * Congenital toxoplasmosis * Isolated ocular toxoplasmosis in immunocompetent individuals
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall patient survival rates | Up to 1 year |
Countries
France
Contacts
Primary ContactMathilde HERBER, MD
Outcome results
None listed